CONCORD, Calif. & DAVENPORT, Iowa--(BUSINESS WIRE)--
Cerus Corporation (NASDAQ:CERS) announced today that the Mississippi
Valley Regional Blood Center (MVRBC) has signed a three-year purchase
agreement for the INTERCEPT Blood System for platelets and plasma.
“With support from our donors, we provide world class blood and blood
components to hospitals throughout our region,” said Mike Parejko,
MVRBC’s Chief Executive Officer. “We do so with an unwavering focus on
the quality and safety of our products. INTERCEPT-treated platelets and
plasma will enable us to offer another safe choice of blood components
to the hospitals we serve.”
The Mississippi Valley Regional Blood Center is the exclusive provider
of blood products and services to 88 hospitals in Illinois, Iowa,
Missouri, and Wisconsin. MVRBC is headquartered in Davenport, Iowa,
where its testing, processing, and primary distribution center handles
more than 400,000 units of blood components annually. The population of
MVRBC’s service region exceeds 4 million residents, and donors give more
than 200,000 donations each year.
ABOUT CERUS
Cerus Corporation is a biomedical products company focused in the field
of blood transfusion safety. The INTERCEPT Blood System is designed to
reduce the risk of transfusion-transmitted infections by inactivating a
broad range of pathogens such as viruses, bacteria and parasites that
may be present in donated blood. The nucleic acid targeting mechanism of
action of the INTERCEPT treatment is designed to inactivate established
transfusion threats, such as Hepatitis B and C, HIV, West Nile Virus and
bacteria, as well as emerging pathogens such as chikungunya, malaria and
dengue. Cerus currently markets and sells the INTERCEPT Blood System for
both platelets and plasma in the United States, Europe, the Commonwealth
of Independent States, the Middle East and selected countries in other
regions around the world. The INTERCEPT red blood cell system is in
clinical development. See www.cerus.com
for more information about Cerus.
INTERCEPT and the INTERCEPT Blood System are trademarks of Cerus
Corporation.
View source version on businesswire.com: http://www.businesswire.com/news/home/20151204005127/en/
Source: Cerus Corporation